• Medientyp: E-Artikel; Sonstige Veröffentlichung
  • Titel: Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections—an Open Observational Study in Lower Saxony, Germany
  • Beteiligte: Jonczyk, Rebecca [VerfasserIn]; Stanislawski, Nils [VerfasserIn]; Seiler, Lisa K. [VerfasserIn]; Blume, Holger [VerfasserIn]; Heiden, Stefanie [VerfasserIn]; Lucas, Henning [VerfasserIn]; Sarikouch, Samir [VerfasserIn]; Pott, Philipp-Cornelius [VerfasserIn]; Stiesch, Meike [VerfasserIn]; Hauß, Corinna [VerfasserIn]; Saletti, Giulietta [VerfasserIn]; González-Hernández, Mariana [VerfasserIn]; Kaiser, Franziska Karola [VerfasserIn]; Rimmelzwaan, Guus [VerfasserIn]; Osterhaus, Albert [VerfasserIn]; Blume, Cornelia [VerfasserIn]
  • Erschienen: Birmingham, Ala. : ASM, 2022
  • Erschienen in: Microbiology spectrum 10 (2022), Nr. 1 ; Microbiology spectrum
  • Sprache: Englisch
  • DOI: https://doi.org/10.15488/12234; https://doi.org/10.1128/spectrum.01512-21
  • Schlagwörter: working groups ; SARS-CoV-2 antibody screening ; PCR ; COVID-19 ; subclinical cases ; neutralizing antibodies ; antibody screening tests
  • Beschreibung: Despite lockdown measures, intense symptom-based PCR, and antigen testing, the SARS-CoV-2 pandemic spread further. In this open observational study conducted in Lower Saxony, Germany, voluntary SARS-CoV-2 PCR tests were performed from April 2020 until June 2021, supported by serum antibody testing to prove whether PCR testing in subjects with none or few symptoms of COVID-19 is a suitable tool to manage the pandemic. In different mobile stations, 4,817 subjects from three different working fields participated in the PCR testing. Serum antibody screening using the SARS-CoV-2 ViraChip IgG (Viramed, Germany) and the Elecsys Anti-SARS-CoV-2 assay (Roche, Germany) was performed alongside virus neutralization testing. Subjects were questioned regarding comorbidities and COVID-19 symptoms. Fifty-one subjects with acute SARS-CoV-2 infection were detected of which 31 subjects did not show any symptoms possibly characteristic for COVID-19. An additional 37 subjects reported a previous SARS-CoV-2 infection (total prevalence 1.82%). Seroconversion was discovered in 58 subjects with known SARS-CoV-2 infection and in 58 subjects that never had a positive PCR test. The latter had a significantly lower Charlson Comorbidity Index, and one third of them were asymptomatic. In 50% of all seroconverted subjects, neutralizing serum antibodies (NAbs) were detectable in parallel to N/S1 (n = 16) or N/S1/S2 antigen specific antibodies (n = 40) against SARS-CoV-2. NAb titers decreased within 100 days after PCR-confirmed SARS-CoV-2 acute infection by at least 2.5-fold. A relatively high rate of subclinical SARS-CoV-2 infections may contribute to the spread of SARS-CoV-2, suggesting that in addition to other intervention strategies, systematic screening of asymptomatic persons by PCR testing may significantly enable better pandemic control.
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)